Actively Recruiting
Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors
Led by Sun Yat-sen University · Updated on 2023-08-29
300
Participants Needed
1
Research Sites
413 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
As the clinical manifestations of pituitary neuroendocrine tumors vary greatly, 2.7-15% of them are resistant to conventional treatments such as surgery, drug therapy and radiotherapy, and often relapse or regrow in the early postoperative period, which is invasive and has a poor prognosis. Therefore, it is important to find imaging, histological or serum molecular markers for early prediction of the invasiveness and clinical prognosis of pituitary neuroendocrine tumors. The aim of this study is to observe the changes of biomarkers and imaging features in serum or tissues of pituitary neuroendocrine tumors during the course of disease and treatment, and to explore the biomarkers and imaging features that can predict the proliferation, progression and recurrence risk of pituitary neuroendocrine tumors after medical or surgical treatment.
CONDITIONS
Official Title
Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with pituitary neuroendocrine tumors confirmed by clinical imaging
- Pituitary hormone secretion status confirmed by hormone detection
- Age between 18 and 70 years
You will not qualify if you...
- Previous pathological diagnosis of pituitary carcinoma
- Prior radiation, chemotherapy, immunotherapy, or targeted therapy
- Known genetic syndromes causing hormone overproduction (e.g., Carney syndrome, McCune-Albright syndrome, multiple endocrine neoplasia type 1)
- Presence of ectopic neuroendocrine tumors
- Major surgery within 1 month before screening or sphenoid pituitary surgery within 3 months before screening
- Crisis of gland function such as pituitary, thyroid, or adrenal crisis
- Severe blood diseases or solid tumors in peripheral glands
- Serious organ damage (heart, kidney, liver, etc.)
- Severe mental or nervous system diseases
- Poorly controlled high blood glucose, hypertension, or emergency conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
endocrinology department of the first affiliated hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510080
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here